368 related articles for article (PubMed ID: 17028476)
1. [An update on multiple insulin injection therapy in type 1 and 2 diabetes].
Varanauskiene E; Varanauskaite I; Ceponis J
Medicina (Kaunas); 2006; 42(9):770-9. PubMed ID: 17028476
[TBL] [Abstract][Full Text] [Related]
2. Insulin analog therapy: improving the match with physiologic insulin secretion.
Freeman JS
J Am Osteopath Assoc; 2009 Jan; 109(1):26-36. PubMed ID: 19193822
[TBL] [Abstract][Full Text] [Related]
3. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
Ilag LL; Kerr L; Malone JK; Tan MH
Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
[TBL] [Abstract][Full Text] [Related]
4. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
5. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
[TBL] [Abstract][Full Text] [Related]
6. Novel insulins: expanding options in diabetes management.
Gerich JE
Am J Med; 2002 Sep; 113(4):308-16. PubMed ID: 12361817
[TBL] [Abstract][Full Text] [Related]
7. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function.
Mayfield JA; White RD
Am Fam Physician; 2004 Aug; 70(3):489-500. PubMed ID: 15317436
[TBL] [Abstract][Full Text] [Related]
8. Insulin glargine: a systematic review of a long-acting insulin analogue.
Wang F; Carabino JM; Vergara CM
Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
[TBL] [Abstract][Full Text] [Related]
9. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
[TBL] [Abstract][Full Text] [Related]
10. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J
Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
[TBL] [Abstract][Full Text] [Related]
11. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
Yki-Järvinen H; Dressler A; Ziemen M;
Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
[TBL] [Abstract][Full Text] [Related]
12. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?
Valensi P; Cosson E
Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S34-4S39. PubMed ID: 16389896
[TBL] [Abstract][Full Text] [Related]
13. Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes.
Chacra AR; Kipnes M; Ilag LL; Sarwat S; Giaconia J; Chan J;
Diabet Med; 2010 May; 27(5):563-9. PubMed ID: 20536953
[TBL] [Abstract][Full Text] [Related]
14. A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study.
Gordon J; Pockett RD; Tetlow AP; McEwan P; Home PD
Int J Clin Pract; 2010 Nov; 64(12):1609-18. PubMed ID: 20946269
[TBL] [Abstract][Full Text] [Related]
15. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.
Vague P; Selam JL; Skeie S; De Leeuw I; Elte JW; Haahr H; Kristensen A; Draeger E
Diabetes Care; 2003 Mar; 26(3):590-6. PubMed ID: 12610006
[TBL] [Abstract][Full Text] [Related]
16. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
Janka HU; Plewe G; Busch K
J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
[TBL] [Abstract][Full Text] [Related]
17. An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.
Raslova K
Vasc Health Risk Manag; 2010 Jun; 6():399-410. PubMed ID: 20539842
[TBL] [Abstract][Full Text] [Related]
18. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens.
Murphy NP; Keane SM; Ong KK; Ford-Adams M; Edge JA; Acerini CL; Dunger DB
Diabetes Care; 2003 Mar; 26(3):799-804. PubMed ID: 12610040
[TBL] [Abstract][Full Text] [Related]
19. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
20. Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes.
Deiss D; Kordonouri O; Hartmann R; Hopfenmüller W; Lüpke K; Danne T
Pediatr Diabetes; 2007 Jun; 8(3):157-62. PubMed ID: 17550426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]